109 citations,
April 2000 in “European Urology” Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.
April 2018 in “The Journal of urology/The journal of urology” A new score can help predict which patients might have trouble urinating after prostate surgery.
3 citations,
June 2017 in “The Journal of urology/The journal of urology” Older men with postoperative urinary retention are more likely to need future bladder procedures.
April 2022 in “Urology Practice” Early intervention for acute urinary retention can reduce costs and improve care.
1054 citations,
February 1998 in “The New England Journal of Medicine” Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.
May 2023 in “The Journal of Urology” 30 citations,
July 2001 in “BJUI” Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.
7 citations,
May 2008 in “PubMed” April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
1 citations,
January 2002 in “European Urology Supplements” Tamsulosin works faster, but both drugs have similar effects after 6 months.
235 citations,
September 2004 in “The Journal of urology/The journal of urology” Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
October 2006 in “Aging Health” Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.
21 citations,
September 2015 in “Current Drug Targets” Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.
24 citations,
February 2012 in “Prostate cancer and prostatic diseases” 5α-reductase inhibitors help shrink the prostate, improve urinary symptoms, and may reduce prostate cancer risk.
23 citations,
June 1999 in “Clinical Therapeutics” Finasteride is a cost-effective option for treating BPH, reducing risk of urinary issues and surgery.
1 citations,
October 2017 in “The Journal of Urology” Long-term medication for enlarged prostate might not clearly affect the timing or outcomes of later surgery.
2 citations,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
April 2015 in “The Journal of Urology” Finasteride reduces PSA levels by around 40-50% in BPH patients.
2 citations,
April 2021 in “Canadian Journal of Urology” Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
1 citations,
September 2023 in “Frontiers in Genetics” A heterozygous mutation in HTRA1 can cause severe CARASIL symptoms.
November 2022 in “American Journal of Clinical Pathology” TURP specimens should be checked for various tumors, not just common prostate issues.
1707 citations,
December 2003 in “The New England Journal of Medicine” Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
184 citations,
January 2000 in “European Urology” Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.
183 citations,
January 1987 in “British Journal of Anaesthesia” Opioid painkillers can cause many side effects, including breathing problems and addiction, but are generally considered safe when used properly.
52 citations,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
45 citations,
January 2008 in “Drugs” Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.
24 citations,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
35 citations,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
24 citations,
September 2008 in “International Braz J Urol” Lovastatin doesn't improve lower urinary tract symptoms treatment.